Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MDXH
MDXH logo

MDXH Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy MDxHealth SA (MDXH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.980
1 Day change
-49.49%
52 Week Range
5.330
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

MDxHealth SA (MDXH) is not a strong buy at this moment for a beginner investor with a long-term strategy. The lack of significant trading trends, absence of recent news or catalysts, and neutral technical indicators suggest no immediate opportunity. Additionally, no proprietary trading signals are present to indicate a strong buy. It would be prudent to monitor the stock for future developments or stronger signals before making an investment decision.

Technical Analysis

The MACD histogram is positive at 0.0485 but contracting, indicating weakening momentum. RSI is neutral at 41.112, and moving averages are converging, showing no clear trend. Key support and resistance levels are Pivot: 2.196, R1: 2.337, S1: 2.054, R2: 2.424, S2: 1.967. Overall, the technical indicators suggest a neutral stance with no strong buy or sell signals.

Positive Catalysts

  • NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

  • No significant negative catalysts, but the stock shows a slight probability of declining in the next week (-0.7%) and month (-1.38%).

Financial Performance

No financial data available for analysis due to an error.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

Wall Street analysts forecast MDXH stock price to rise
5 Analyst Rating
Wall Street analysts forecast MDXH stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.985
sliders
Low
7
Averages
7.67
High
9
Current: 0.985
sliders
Low
7
Averages
7.67
High
9
William Blair
Outperform -> Market Perform
downgrade
$NULL
AI Analysis
2026-05-14
New
Reason
William Blair
Price Target
$NULL
AI Analysis
2026-05-14
New
downgrade
Outperform -> Market Perform
Reason
William Blair downgraded MDxHealth to Market Perform from Outperform without a price target. The company's Q1 revenue came in well below expectations and its full-year revenue guidance was cut by just under 20% at the midpoint, the analyst tells investors in a research note. The firm says given the given the uncertainty associated with the reimbursement environment for Resolve in this non-MolDX jurisdiction, MDxHealth is exiting the Resolve business and closing the Texas lab. "This is at least a near-term shock to the thesis," the firm says.
Lake Street
analyst
Buy
downgrade
$9 -> $5
2026-05-14
New
Reason
Lake Street
analyst
Price Target
$9 -> $5
2026-05-14
New
downgrade
Buy
Reason
Lake Street lowered the firm's price target on MDxHealth to $5 from $9 and keeps a Buy rating on the shares. MDxHealth announced its Q1 results and the discontinuation of its Resolve UTI business following an unexplained policy reversal by Novitas, notes the analyst, who says the "headline is the strategic exit, not the print." MDxHealth reset 2026 revenue guidance to to reflect the Resolve exit, adds the analyst, who remains confident in the future of the core prostate cancer business but realizes "management will be in the penalty box for a quarter or two as these changes are absorbed and performance is demonstrated."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MDXH
Unlock Now

People Also Watch